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 Introduction 
 Only recently have the frequency and relevance of 
nonmotor disturbances (NMDs) of Parkinson’s disease 
(PD) been recognized. Accordingly, a questionnaire ad-
dressing nonmotor symptoms in PD was recently devel-
oped and used in an international multicenter pilot study 
 [1] . Also, the new, revised Uniﬁed Parkinson’s Disease 
Rating Scale takes NMDs into account more thoroughly 
 [2] . Finally, in 2010, the American Academy of Neurology 
issued a practice parameter paper about treatment of 
NMDs. Only sildenafil citrate (for erectile dysfunction), 
macrogol (polyethylene glycol for constipation) and le-
vodopa/carbidopa (for spontaneous nighttime leg move-
ments) were considered to be sufficiently proven to be 
effective in PD (evidence level B or C)  [3] .
 Some NMDs have a diagnostic value because they ap-
pear early in the course of PD and may precede the onset 
of motor symptoms. Other NMDs typically appear later 
and have a profound impact on the quality of life of PD 
patients.
 Based not only on clinical but also neuropathological 
data, PD, which was traditionally seen as a dopaminergic 
motor disorder, can now be viewed as a multisystem neu-
rodegenerative disease that often involves other neu-
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rotransmitter systems and affects nonmotor functions. 
This paper reviews the clinical features, underlying 
mechanisms, diagnosis and treatment of neuropsychiat-
ric/cognitive, sleep-wake, autonomic and sensory distur-
bances in PD.
 Neuropsychiatric/Cognitive Disturbances 
 Depression 
 Clinical Features  
 Depression is found in 25–50% of PD patients and can 
appear early in the course of PD  [4] . Suicidal ideations 
may be present in up to 10% of patients. Conversely, se-
vere depression and suicide attempts are rather uncom-
mon. They have been reported following subthalamic 
stimulation  [5] .
 Depression is associated with apathy, anxiety, exces-
sive daytime sleepiness (EDS), cognitive decline and 
poor quality of life  [6, 7] . In addition, dysphoria and de-
pression predispose to impulse control disorders (ICDs) 
in PD.
 Mechanisms  
 Impaired dopaminergic and probably later in the 
course of PD also serotonergic and noradrenergic trans-
mission in the ventral striatum and limbic system has 
been suggested as a possible mechanism  [4, 8] . A familial 
predisposition has also been observed  [4] .
 Abrupt cessation of dopaminergic drugs can lead to 
depression/suicidal thoughts. Depression can also appear 
acutely as a nonmotor fluctuation manifestation or fol-
lowing high-frequency deep brain stimulation  [9] .
 Psychoreactive mechanisms may also be involved in 
PD-associated depression.
 Diagnosis  
 Apathy, fatigue, sleepiness and slow motion can be dif-
ficult to differentiate from (and do actually commonly 
coexist with) depression. The Beck Depression Inventory 
and the Hamilton Depression Rating Scale have been 
used to assess depression in PD, although some physical 
symptoms of depression might overlap with those of PD 
 [10] .
 Treatment 
 Pramipexole, ropinirole and other dopaminergic 
agents/drugs may improve depression, particularly in 
the early course of PD  [4, 11] . Antidepressants (amitrip-
tyline, nortriptyline), selective serotonin reuptake inhib-
itors (SSRIs; e.g. venlafaxine) and noradrenaline reup-
take inhibitors (e.g. reboxetine) have been shown in a few 
studies to improve mood in PD  [4, 12] . However, their 
potential side effects [including orthostatic hypotension 
(OH) and cognitive side effects] should be considered. 
Mirtazapine is better tolerated in advanced PD [pers. ob-
servation].
 In patients with PD, depression and hypersomnia/
EDS/fatigue, reboxetine and venlafaxine are preferable. 
Conversely, in PD patients with insomnia, mirtazapine 
could be tried first.
 Anxiety and Panic Attacks 
 Clinical Features  
 Panic attacks, phobias and anxiety are seen in about 
40% of PD patients  [4] . They can appear early in the 
course of PD but may also be seen in the context of non-
motor fluctuations (‘off states’) of more advanced PD.
 Anxiety is associated with depression and insomnia.
 Mechanisms  
 The role of dopamine and other neurotransmitters re-
mains speculative. Anxiety and panic attacks, often in 
association with other psychiatric and somatic symptoms 
(such as depression, dysphoria, sweating, pain and OH), 
can be observed in the course of withdrawal from dopa-
minergic drugs, in particular agonists (the so-called do-
pamine agonist withdrawal syndrome)  [13] .
 Diagnosis  
 The Hospital Anxiety and Depression Scale and other 
anxiety scales have been suggested, but their validity has 
not been well assessed  [4] .
 Treatment  
 There are only poor data about the treatment of anxi-
ety in PD. Dopaminergic drugs, SSRIs and benzodiaze-
pines may be useful. However, the latter can worsen gait, 
cognition and sleep breathing. Deep brain stimulation 
may also lead to an improvement in anxiety  [11] .
 Impulse Control Disorders 
 Clinical Features  
 ICDs include a series of disturbances such as compul-
sive gambling and shopping; binge eating; hypersexuali-
ty; punding (abnormal, repetitive, meaningless activities, 
obsessive cleaning, arranging); compulsive medication 
use (so-called hedonistic homeostatic dysregulation or 
dopamine dysregulation syndrome); hobbyism ( fig.  1 ), 
and excessive, aimless wandering or driving  [14–16] . This 
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spectrum of disorders is associated with significant psy-
chosocial distress and consequences.
 The frequency of ICDs in PD is poorly known; it may 
range from 1 to 14% and largely depends on the diagnos-
tic criteria used and the specific type of ICD considered 
 [16, 17] .
 Young age of onset, male gender, higher doses of short-
acting dopaminergic drugs (in particular dopamine ago-
nists), psychiatric comorbidities, pre-existing drug or al-
cohol use and a novelty-seeking personality are linked 
with ICDs  [18] . A recent large-scale study suggested that 
dopamine agonist treatment in PD is associated with 2- to 
3.5-fold increased odds of having ICDs  [19] . Cases of ICD 
induced (but also improved) by deep brain stimulation 
have also been reported.
 Mechanisms 
 Overactivity of dopamine (basal ganglia) and under-
activity of inhibitory (prefrontal) pathways have been 
suggested as mechanisms causing ICDs  [15] . Neuroimag-
ing studies have documented changes in the ventral stri-
atum and prefrontal cortex  [20] . The role of dopamine 
treatment is underscored by the observation that ICD is 
also present in patients with restless legs syndrome (RLS) 
 [22] .
 Diagnosis 
 Patients rarely report ICDs, which often remain un-
recognized. A recently developed, 30-question screening 
questionnaire was reported to have a  1 80% sensitivity 
(but a low specificity) for ICDs in PD  [17] .
 Treatment  
 Reduction/cessation/change of dopaminergic drugs, 
use of new antipsychotic drugs, cognitive-behavioral 
treatments and psychological support/interventions can 
completely reverse ICDs in individual patients. However, 
the general prognosis of ICDs in PD is unclear  [22] .
 Hallucinations/Illusions/Psychosis 
 Clinical Features  
 When systematically searched for, mild hallucinations 
and illusions (misperception of real stimuli) are found in 
up to 50% of patients with PD  [23] . The onset of halluci-
nations within the first 3 years of PD suggests a diagnosis 
of dementia with Lewy bodies (DLB)  [24] .
 Visual hallucinations/illusions are most commonly 
observed  [25] . Typically, faces and persons (familiar or 
unfamiliar) and, less commonly, animals or objects are 
reported ( fig. 2 ). Hallucinations in other modalities (in-
cluding the tactile and olfactory domains) as well as mul-
timodal hallucinations are possible  [26] . Mild forms of 
hallucinations and illusions include the vague, fleeting 
vision of a passing animal/object (‘passing illusions’) and 
of the presence of a person (‘sensed presence’). Capgras 
syndrome and other misidentification disturbances can 
also be observed. Insight may be preserved, particularly 
in cognitively intact patients. Hallucinations are more 
common during the wake-sleep transition and in the 
dark.
 Hallucinations are associated with cognitive decline, 
depression, anxiety, sleep-wake disturbances and vivid 
dreaming  [27] . Severe, frequent and chronic hallucina-
tions (and psychosis) are a risk factor for nursing home 
placement and death.
 Mechanisms  
 Mesopontine/limbic cholinergic underactivity and 
striatal dopaminergic overactivity have been discussed 
 [28] . However, dopamine appears to be neither sufficient 
nor necessary for the occurrence of hallucinations in PD 
(for this reason, the use of the term ‘dopamine psychosis’ 
is not recommended). Abnormal activation of the higher-
order visual (visuoperceptual) cortex, but also dysfunc-
tion of amygdaloid and retinal circuits have also been
discussed  [29] . Damage to the left hemisphere (right-
predominant motor symptoms) has been linked with
PD-related psychosis  [30] .
 Diagnosis  
 Patients are reluctant to report hallucinations. How-
ever, the recognition of mild hallucinations is important 
to prevent PD-related psychosis. Tools for the recognition 
of PD-associated psychosis have been developed but not 
yet validated  [31] .
 Treatment  
 Reduction of dopaminergic drugs is often but not al-
ways effective/sufficient in improving hallucinations/il-
lusions. Reduction of anxiety and sleepiness may have a 
positive effect. Hospitalization may reduce (but occasion-
ally also worsen) hallucinations. Improvement of coping 
strategies should be considered. Low-dose clozapine (typ-
ically, 6.25–50 mg are sufficient) improves hallucinations 
without worsening motor functions  [32, 33] and appears 
to be superior to quetiapine  [4] . Cholinesterase inhibitors 
may also be effective in reducing hallucinations and delu-
sions by simultaneously exerting beneficial effects on 
cognition.
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 Fig. 2. A 70-year-old woman with mild PD had visual hallucinations (the face of her father) that she always per-
ceived when staring at the chair of her living room. On the right, the visual misperception of the patient is re-
constructed (with a projection of a picture of her father) [Brugger A., Bassetti C., unpubl. observations]. 
 Fig. 1. A 60-year-old architect with mild PD and dopamine dysregulation syndrome (hedonistic homeostatic 
syndrome) who used to make drawings and sketches in the past started in the course of his neurological disor-
der to produce large, complex and colorful paintings. He reports that these paintings are done ‘as if in a trance’, 
without preparation and ‘just like that’ in a few minutes. 
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 Dementia 
 Clinical Features  
 Dementia is present in up to 80% of PD patients to-
wards the end of their life  [34, 35] . The onset of dementia 
within the first year of PD (‘1-year rule’) suggests a diag-
nosis of DLB  [24] .
 Clinically, patients present with dysexecutive syn-
drome (short attention span, poor working memory, dif-
ficulty in planning/set-shifting/multitasking, reduced 
drive/psychomotor slowing, decreased verbal fluency, 
perseverations) and visuospatial deficits. Cognition and 
attention typically fluctuate; patients exhibit daytime 
drowsiness and lethargy, daytime sleep of 2 or more 
hours, episodes of staring into space for long periods and 
episodes of disorganized speech  [36] . Memory and lan-
guage deficits are observed only later in the course of PD 
dementia (PDD), where memory retrieval in the free re-
call mode is typically more compromised than cued re-
call.
 Hallucinations, depression, EDS, sleep disturbances 
and urinary incontinence are frequently found in pa-
tients with PDD  [35, 37] .
 Mechanisms  
 Nigrostriatal and mesolimbic dopamine deficits have 
been linked to executive disturbances. Cholinergic defi-
cits in the nucleus basalis of Meynert and cortical neuro-
nal loss are considered essential for PDD. Other transmit-
ter deficits, noncortical (e.g. limbic) changes and con-
comitant Alzheimer’s disease-like pathology probably 
also play a role  [38] .
 Similar morphological and functional (e.g. brain PET) 
findings in PDD and DLB, together with overlapping 
clinical features, suggest that the two disorders actually 
represent different degrees of a single disorder  [39] .
 Diagnosis  
 Verbal fluency, Wisconsin card sorting and the Stroop 
test are useful to assess executive functions. However, 
there are only few systematic data on screening and as-
sessment scales for cognitive changes in patients with PD 
 [40–43] . The Mini-Mental State Exam has a much lower 
sensitivity for the diagnosis of PDD than the Montreal 
Cognitive Assessment and even the clock drawing test 
alone ( fig. 3 )  [42, 44] .
 Treatment  
 Dopaminergic drugs but also atomoxetine have been 
shown to improve executive functions  [45, 46] . Donepe-
zil, rivastigmine and more recently also memantine have 
been shown to improve PDD and DLB  [47–49] . Rivastig-
mine was recently approved for PDD. Guidelines for the 
management of PDD have recently been published  [50] .
 Sleep-Wake Disturbances 
 REM Sleep Behavior Disorder 
 Clinical Features  
 REM sleep behavior disorder (RBD) corresponds to 
dream enactment behavior during REM sleep. Patients 
experience vivid, frightening dreams, leading to vocal-
izations (talking, shouting, screaming, yelling), violent 
behaviors (kicking, punching, assaults) and injuries.
 RBD is estimated to occur in 25–50% of PD patients 
 [51, 52] . This parasomnia of REM sleep can precede the 
onset of PD by over 10 years  [53] . Idiopathic RBD is as-
sociated with subtle memory, color discrimination, olfac-
tory and finger tapping deficits which are consistent with 
an early (preclinical) PD stage  [54] . Most patients with 
idiopathic RBD eventually develop a neurodegenerative 
disorder (including PD) over the course of time  [55, 56] .
 In patients with PD, RBD is associated with sleep dis-
ruption and hallucinations but not with gait impairment/
postural instability  [57, 58] .
 Fig. 3. Clock drawing by a 74-year-old patient with PD and mild 
dementia. 
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 Mechanisms  
 Loss of physiological muscle tone and increase in pha-
sic motor activity during REM sleep are the hallmarks of 
RBD ( fig. 4 )  [59] . Changes in GABA, dopamine and cho-
linergic transmission in brainstem (pontomesencephal-
ic) and limbic (amygdaloid) pathways have been postu-
lated  [59, 60] .
 Diagnosis  
 Recently, a 10-question screening tool was developed 
and validated for RBD  [57, 61] . The sensitivity is high but 
the specificity is relatively low.
 Treatment  
 Clonazepam (05–2.0 mg at bedtime) but also dopami-
nergic drugs and melatonin can improve RBD  [59] . Mir-
tazapine, venlafaxine, tricyclic antidepressants and SSRIs 
have been reported to trigger/worsen RBD in PD  [59, 62] .
 Sleepwalking 
 Clinical Features 
 Sleepwalking corresponds to a complex sleep-associ-
ated behavior, which includes locomotion, mental confu-
sion and amnesia for the episode. Self-inflicted injuries 
and acts of violence as well as episodes of sleep eating 
(somnophagia) may also occur  [63] . A recent systematic, 
questionnaire-based survey of 417 patients suggested a 
9% frequency of sleepwalking in PD [Oberholzer et al., in 
preparation]. Half of these patients first developed sleep-
walking as adults. Sleepwalking was associated with 
RBD, nightmares and hallucinations.
 Mechanisms  
 Deficient (ascending) mechanisms of arousal and 
(descending) mechanisms of motor and muscle tone 
control have been postulated for both RBD and sleep-
walking.
 Fig. 4. An 82-year-old man with mild par-
kinsonism and RBD. According to his 
wife, he displayed frequent vocalizations 
and violent behavior during sleep. Poly-
somnographic recordings show loss of 
normal muscle atonia during REM sleep 
and increased phasic muscle activity as 
well as acting out of dreams with kicking 
and menacing gestures. 
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 Diagnosis  
 The differentiation between RBD and sleepwalking 
may be difficult based on history alone; in addition, the 
conditions may coexist (see above). The polysomno-
graphic characteristics of PS patients with sleepwalking 
are essentially unknown.
 Treatment  
 There are no data on treatment of sleepwalking in PD.
 RLS and Periodic Limb Movements in Sleep 
 Clinical Features 
 Typical RLS may precede or (more commonly) follow 
the onset of PD. It is usually mild. RLS-like sensory symp-
toms are not unusually reported during wearing-off and 
off periods but also in dystonic/dyskinetic and (external 
or internal) tremulous states  [64] . Distinguishing be-
tween RLS and RLS-like symptoms in patients with fluc-
tuating PD is, in fact, difficult; this may explain the wide 
range (0–52%) of RLS frequency in PD reported in the 
literature  [65–67] .
 Most PD patients are not aware of periodic limb move-
ments in sleep (PLMS). The exact frequency of PLMS in 
PD is poorly known  [67] . RLS and PLMS may improve or 
worsen (maybe because of a dopaminergic withdrawal) 
after deep brain stimulation.
 RLS and PLMS may contribute to insomnia, EDS and 
daytime fatigue in PD.
 Mechanisms  
 Reduced striatal dopaminergic transmission and low 
ferritin levels have been postulated to explain RLS and 
PLMS in PD  [67, 68] .
 Diagnosis  
 Clinically typical RLS and RLS-like symptoms due to 
fluctuating PD symptoms or anxiety/depression may be 
difficult to diagnose. The diagnosis of PLMS requires a 
nocturnal polysomnography or a leg actigraphy.
 Treatment  
 Extended-release dopamine agonists such as rotigo-
tine and monoamine oxidase B inhibitors such as rasagi-
line may be particularly beneficial for RLS/PLMS in PD 
[pers. observation].
 Excessive Daytime Sleepiness 
 Clinical Features  
 EDS is present in 25–50% of PD patients and may lead 
to sudden sleep episodes (‘sleep attacks’)  [69–71] . It is not 
uncommon for patients to underestimate the severity of 
EDS (as estimated by subjective and objective measures). 
The frequency of sleep attacks in PD ranges from 1 to 27% 
in the literature  [70] .
 The severity of PD, antiparkinsonian drugs (dopa-
mine agonists), sleep disturbances (including sleep-dis-
ordered breathing and RLS/PLMS) and dementia are as-
sociated with EDS in PD  [37, 72] . Treatment with dopa-
mine agonists has been implicated in the appearance of 
sleep attacks  [69, 73–75] . On rare occasions, severe EDS 
may appear in young patients early in the course of PD 
without medication  [76] . Sleep deprivation can play a 
role, particularly in patients with dopamine overuse/dys-
regulation syndrome.
 An overlap exists between EDS, sleep attacks and fluc-
tuations in PD patients with dementia and DLB.
 Mechanisms  
 Several factors in addition to neurodegeneration of 
neuronal pathways necessary for the maintenance of 
wakefulness may contribute to EDS (see above). Patients 
with advanced PD present a 20–30% reduction of hypo-
cretin neurons in the lateral hypothalamus  [77] . Howev-
er, most PD patients, even those with EDS, have normal 
cerebrospinal fluid hypocretin levels  [37, 78–80] .
 Diagnosis  
 An Epworth Sleepiness Score of  1 10 indicates the pres-
ence of EDS. A short mean sleep latency ( ! 5 min) is found 
in 20–30% of PD patients  [70] . A correlation between sub-
jective (Epworth Sleepiness Score) and objective EDS (as 
assessed for example with the Multiple Sleep Latency 
Test) exists in PD patients  [72] . Sleep-onset REM episodes 
were found to be frequent in some but not all systematic 
studies  [79, 81, 82] .
 Treatment  
 Change in medication and treatment of sleep distur-
bances (including sleep-disordered breathing) may im-
prove EDS in PD. Naps distributed over the day may
effectively reduce sleep pressure [pers. observation]. 
Modafinil has been shown in some but not all studies to 
improve EDS in PD  [83–85] .
 More recently, sodium oxybate was found to improve 
EDS and fatigue and an inverse agonist of the histamine 
H 3 receptor to improve EDS in PD  [86, 87] .
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 Fatigue and Apathy 
 Clinical Features  
 Fatigue corresponds to a subjective feeling of exhaus-
tion, lack of energy, physical and mental tiredness (cen-
tral fatigue) and decreased force generation or rapid fati-
gability (peripheral fatigue). Apathy is defined as a disor-
der of motivation with diminished goal-oriented behavior 
and cognition. Fatigue and apathy are often unrecog-
nized, although systematic studies have shown that they 
may be present in up to 50% of PD patients  [4, 71, 88] . Fa-
tigue can be very disabling in up to 1/3 of patients and 
appears early in the course of PD  [4] . In PD, fatigue is as-
sociated with depression, PD severity and sleep distur-
bances  [4, 71] . Apathy has been linked mainly to depres-
sion and cognitive decline  [88, 89] . Isolated apathy was 
recently found to represent a risk factor for the subse-
quent development of dementia  [90] . Fatigue – often in 
association with other psychiatric and somatic symptoms 
(see above) – can also be observed in the course of with-
drawal from dopaminergic drugs, in particular agonists 
 [13] . Finally, deep brain stimulation can also induce apa-
thy  [91] .
 Mechanisms  
 Fatigue and apathy are thought to arise from the in-
volvement of dopaminergic (e.g. ventral tegmentum-nu-
cleus accumbens) and nondopaminergic (frontosubcorti-
cal circuits) mediation of goal-oriented and reward be-
haviors.
 Diagnosis  
 Apathy, depression and fatigue are sometimes difficult 
to differentiate because of similar comorbidities and 
overlapping clinical characteristics. The Fatigue Severity 
Scale, the Parkinson Fatigue Scale and the Apathy Evalu-
ation Scale have been used as diagnostic tools in PD  [71, 
91–93] .
 Treatment  
 Dopaminergic drugs (e.g. ropinirole) can improve fa-
tigue and apathy, particularly early in the course of PD; 
methylphenidate can improve central fatigue and levodo-
pa peripheral fatigue  [4] . Modafinil improves EDS but 
not fatigue  [94] . Sodium oxybate can improve fatigue and 
EDS  [86] .
 Insomnia 
 Clinical Features  
 Sleep induction and maintenance problems are fre-
quent ( ! 50% of PD patients) and may fluctuate over time 
 [95, 96] . Insomnia is more common in female patients 
with depression and long disease duration  [96] .
 Anxiety/depression, hallucinations, tremor, RLS and 
the use of activating drugs (e.g. SSRIs) are associated with 
sleep onset insomnia in PD. On the other hand, PLMS, 
sleep-disordered breathing, nycturia, nightmares, motor 
off symptoms/early-morning foot dystonia and motor 
hyperactivity in sleep/parasomnias are linked to sleep 
maintenance insomnia in PD.
 Mechanisms  
 Insomnia in PD is often multifactorial. Neurodegen-
eration per se, PD motor and nonmotor manifestations, 
drugs and concomitant disorders may cause insomnia.
 Diagnosis  
 Sleep questionnaires, including the Parkinson Disease 
Sleep Scale  [97] , as well as wrist actigraphy can be used 
for screening of sleep disorders/insomnia in PD. Video-
polysomnography may be considered in unclear and 
treatment-unresponsive cases.
 Treatment  
 Extended-release dopamine agonists can improve 
nocturnal sleep in PD, but the scientific evidence for this 
effect is poor. Zolpidem, clozapine and sedating antide-
pressants have also been used for insomnia in PD  [98] . 
Deep brain stimulation was reported to consolidate sleep 
and improve sleep architecture  [99] . Bright light in the 
morning hours may improve insomnia and daytime 
sleepiness, but also cognition, depression and even motor 
functions in advanced/fluctuating PD  [100, 101] .
 Snoring/Sleep-Disordered Breathing
(‘Sleep Apnea’)/Other Breathing Sounds 
 Clinical Features 
 Snoring and sleep-disordered breathing are more 
common in PD patients (particularly those with EDS) 
than controls and may have an impact on sleep and wake-
fulness. However, only limited data are available on this 
association  [79, 102, 103] .
 Nocturnal inspiratory stridor (a high-pitched sound 
which resembles a donkey braying) and expiratory pho-
nation can be observed in PD and other parkinsonian 
syndromes (e.g. multisystem atrophy).
 Mechanisms  
 Snoring and sleep-disordered breathing are the expres-
sion of insufficient patency of the upper airway during 
sleep (with turbulent air flow), which in turn may be re-
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lated to neurodegeneration per se, medications or associ-
ated disorders (e.g. obesity). Inspiratory stridor is typical 
for multisystem atrophy and is due to laryngospasm or 
dystonia from neurodegeneration or mechan ical causes, 
including excessive respiratory secretions  [104, 105] .
 Diagnosis  
 Respirography and video-polysomnography are neces-
sary to diagnose sleep-disordered breathing and stridor.
 Treatment  
 Continuous positive airway pressure is the treatment 
of choice for sleep-disordered breathing and stridor  [106] . 
However, there are almost no data on the effect of con-
tinuous positive airway pressure in sleep-disordered 
breathing in PD. Dopaminergic drugs can improve noc-
turnal expiratory phonation but worsen inspiratory stri-
dor (dystonia).
 Autonomic Disturbances 
 Orthostatic Hypotension 
 Clinical Features  
 OH (defined as a fall in systolic blood pressure of at 
least 20 mm Hg) is found in 20–50% of PD patients and 
is associated with advanced age, male gender and dura-
tion and severity of PD  [107, 108] . OH is often asymptom-
atic in PD. Severe and symptomatic OH early in the 
course of parkinsonism suggests a diagnosis of an atypi-
cal Parkinson syndrome  [109] .
 OH, often in association with other psychiatric and 
somatic symptoms (see above), can be observed in the 
course of withdrawal or, paradoxically, also potentiation 
of dopaminergic drugs ( fig. 5 ), in particular agonists  [13] .
 OH is associated with other signs of dysautonomia 
(e.g. constipation, bladder disturbances, hyperhidrosis, 
erectile dysfunction) as well as with balance problems 
and falls  [10, 110] .
 Mechanisms  
 Vasomotor and cardiac sympathetic dysfunction due 
to neurodegeneration of autonomic nuclei and pathways 
is thought to cause OH  [108] . Cardiac sympathetic dys-
function can be demonstrated by  123 I-MIBG cardiac scin-
tigraphy  [108] .
 Diagnosis  
 Orthostatic symptoms are not very sensitive for the 
presence of OH in PD patients  [111] . Blood pressure 
should be measured on standing for more than 3 min be-
cause the appearance of OH may be delayed  [111] . The 
Scale for Outcomes in PD for Autonomic Symptoms 
(SCOPA-AUT) questionnaire, developed to assess au-
tonomic dysfunction in PD, includes 3 cardiovascular 
items  [112] .
 Treatment  
 Nonpharmacological measures (drinking water in the 
morning before standing, leg crossing, elastic bandage, 
increased water/salt intake distributed during the day) as 
well as such drugs as fludrocortisone, domperidone, mi-
dodrine and pyridostigmine have been shown to improve 
OH in PD  [113, 114] .
 Bladder Disturbances 
 Clinical Features  
 Urinary disturbances are present in 25–50% of pa-
tients with PD  [115, 116] . They are more often irritative 
(nocturia, frequency, urgency, urge incontinence) and 
typically follow the onset of motor disturbances. Ob-
structive/voidance symptoms (hesitancy, weak urinary 
stream) are less common.
 Mechanisms  
 Irritative symptoms are related urodynamically to de-
trusor hyperreflexia, which is linked to altered dopami-
 Fig. 5. Brain CT of an 83-year-old patient with severe parkinson-
ism and subdural hematoma following a fall with severe head 
trauma caused by OH. 
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nergic transmission in PD. Obstructive symptoms may 
be related to a voluntary contraction of the perineal floor 
(to prevent incontinence, pseudodyssynergia) and sphinc-
ter bradykinesia. Obstructive symptoms can also be sec-
ondary to anticholinergics and anatomical obstruction. 
Subthalamic deep brain stimulation can cause urinary 
retention  [117] .
 Diagnosis  
 The SCOPA-AUT questionnaire, developed to assess 
autonomic dysfunction in PD, includes 6 urinary items 
 [112] . Urodynamic studies and sphincter electromyogra-
phy are often needed to correctly interpret urinary dis-
turbances in PD  [10, 118] .
 Treatment  
 Anticholinergics, oxybutynin, tolterodine and botuli-
num toxin A injections can improve urinary frequency 
 [10, 119, 120] . Levodopa can improve or worsen bladder 
disturbances. Rotigotine and deep brain stimulation have 
been shown to have a beneficial effect on bladder func-
tion  [11] .
 Gastrointestinal Disturbances 
 Clinical Features  
 Constipation and delayed gastric emptying are among 
the most common nonmotor symptoms of PD and can 
precede the onset of motor disturbances by years  [121] . 
Abnormal salivation and dysphagia are less common. 
Constipation and nausea can also result from dopami-
nergic treatment.
 Mechanisms  
 Direct involvement of the gut (including degeneration 
of the colonic myenteric plexus) but also central (brain-
stem) mechanisms have been discussed.
 Diagnosis  
 The SCOPA-AUT questionnaire, developed to assess 
autonomic dysfunction in PD, includes 7 gastrointestinal 
items  [112] . The Swallowing Disturbance Questionnaire 
and Dysphagia-Specific Quality of Life are currently sug-
gested for the diagnosis/assessment of sialorrhea in PD 
 [122] .
 Video esophagram, dynamic abdominal scintigraphy 
(for gastric emptying), colon transit studies, defecogra-
phy and anorectal manometry have only rarely been sys-
tematically assessed in PD patients.
 Treatment  
 Dopaminergic drugs do not improve constipation, 
which can be treated with dietary adjustments, oral laxa-
tives (such as macrogol/polyethylene glycol), supposito-
ries, botulinum toxin A injections (for outlet obstruc-
tion), sacral nerve stimulation and colostomy  [3, 120] .
 Sexual Dysfunction 
 Clinical Features  
 Sexual dysfunction can be disabling but is usually not 
assessed and goes unrecognized in PD. Erectile dysfunc-
tion (impotence) and loss of libido, as well as hypersexu-
ality, are most commonly observed. The frequency of 
compulsive sexual behavior in PD patients may be as high 
as 10%  [6] .
 Mechanisms  
 Neurobiological as well as psychosocial factors but 
also medications play a role in sexual dysfunction. A sig-
nificant percentage of patients who have received deep 
brain stimulation report sexual disturbances  [10] . Pa-
tients with the dopamine overuse (dopamine dysregula-
tion) syndrome present hypersexuality and sometimes 
paraphilia.
 Diagnosis  
 There is only one questionnaire that has been validat-
ed for the assessment of impulsive-compulsive disorders 
(including sexual dysfunction) in PD  [17] .
 Treatment  
 The effects of dopaminergic drugs on erectile dys-
function and loss of libido in PD are unknown. Sildenafil 
and other phosphodiesterase type 5 inhibitors can be 
used for erectile dysfunction  [3, 120] .
 Sialorrhea (Drooling) 
 Clinical Features  
 Sialorrhea affects about 50% (32–74%) of PD patients 
 [123] . Frequent drooling is reported less commonly and 
is associated with advanced stages of PD. Sialorrhea is 
associated with significant psychosocial distress and iso-
lation. Furthermore, it can lead to aspiration pneumo-
nia.
 Mechanisms  
 Impaired or infrequent swallowing, rather than hy-
persecretion, are considered the cause of sialorrhea.
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 Diagnosis  
 The Drooling Severity and Frequency Scale, the Drool-
ing Rating Scale and the Sialorrhea Clinical Scale for PD 
are currently suggested for the diagnosis/assessment of 
sialorrhea in PD  [122] .
 Treatment  
 Anticholinergics, botulinum toxin, surgical interven-
tions, radiotherapy, speech therapy and trials of devices 
can improve sialorrhea in PD  [124] . Recently, 1 mg of oral 
glycopyrrolate 3 times daily was shown to be superior to 
placebo for sialorrhea in PD patients (class I evidence) 
 [120, 125] .
 Sensory Disturbances 
 Olfaction 
 Clinical Features 
 Decreased olfactory function is present in  1 70% of pa-
tients with PD  [126] . Patients usually do not report chang-
es in smell. Specific odors such as those for banana, cin-
namon and pineapple may be preferentially affected 
 [127] . Some patients may complain of altered/distorted 
smell (‘smoky odor’). Olfactory dysfunction is typically 
bilateral and may precede the onset of motor symptoms 
of PD by years  [128] . An association between olfactory 
dysfunction and idiopathic RBD has been found  [129] .
 An association between anosmia and autonomic fail-
ure has recently been recognized  [126] .
 Mechanisms  
 Nondopaminergic degeneration of the olfactory bulb 
and the olfactory system has been demonstrated to occur 
early in the course of PD  [130] .
 Diagnosis  
 Olfactory acuity, identification, discrimination and 
memory can be tested with so-called ‘Sniffin sticks’ and 
the University of Pennsylvania Smell Identification Test 
 [126, 131] .
 Treatment  
 No treatment for smell disturbances is known.
 Sensory Symptoms/Pain 
 Clinical Features  
 Sensory symptoms, including pain and burning pain 
in the extremities and trunk, are present in about 50% of 
patients and may precede the onset of motor symptoms 
of PD  [132–134] . Musculoskeletal pain often involves the 
body side in which PD motor symptoms first appear. 
Dystonic pain appears often during wearing-off phases 
and early morning hours. Pain, often in association with 
other psychiatric and somatic symptoms (see above), can 
be observed in the course of withdrawal from dopami-
nergic drugs, in particular agonists  [13] . Neuropathic 
(e.g. burning) pain may involve oral and genital areas and 
may be more common in advanced PD  [135] . Patients 
with PD also exhibit a higher frequency of radicular pain/
problems than the general population. RLS-like symp-
toms in PD (see above) may become painful.
 An association between pain and depression is known 
in PD.
 Mechanisms  
 Pain may be related to motor dysfunction/fluctuations 
and secondary causes (musculoskeletal changes). Central 
neuropathic mechanisms may also play a role  [134] .
 Diagnosis  
 Only a few systematic studies, for example using the 
Brief Pain Inventory, have examined pain in PD  [134] .
 Treatment  
 A possible underlying cause/component of pain other 
than PD should be investigated and, if present, treated. 
Methylphenidate, dopaminergic drugs and deep brain 
stimulation can directly improve pain due to PD  [136, 
137] .
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